Quest Diagnostics price to free cash flow DGX
Market value divided by free cash flow over the last twelve months, since 2010.
- Today, Nov 3, 2026
- 20.0×
- 10-year median
- 16.1×
- Against its 10-year history
- 93rd
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 8.0× to 26.8×
- Peer median
- 34.3×
Quest Diagnostics' price to free cash flow is 20.0× as of Nov 3, 2026.
That is above its ten-year median of 16.1×, higher than on 93% of days in the last ten years.
Over that time it ranged from 8.0× in Jul 2021 to 26.8× in Jan 2024.
The median for 10 diagnostics and research stocks of a similar size is 34.3×.
Price to free cash flow over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 20.1× | 13.9× | 20.2× |
| 2025 | 14.1× | 14.1× | 21.4× |
| 2024 | 16.7× | 15.7× | 26.8× |
| 2023 | 26.0× | 11.1× | 26.0× |
| 2022 | 12.2× | 8.6× | 12.2× |
| 2021 | 11.3× | 8.0× | 12.6× |
| 2020 | 11.6× | 11.6× | 21.5× |
| 2019 | 17.7× | 12.3× | 17.8× |
| 2018 | 12.2× | 12.2× | 17.8× |
| 2017 | 15.6× | 14.6× | 18.7× |
| 2016 | 16.4× | 14.4× | 19.7× |
| 2015 | 17.5× | 15.2× | 18.8× |
| 2014 | 17.8× | 12.2× | 20.5× |
| 2013 | 13.0× | 8.8× | 15.2× |
| 2012 | 9.4× | 9.3× | 13.4× |
| 2011 | 12.9× | 9.5× | 13.1× |
| 2010 | 9.7× | 7.9× | 12.9× |
Against its peers
Companies in Medical - Diagnostics & Research nearest Quest Diagnostics' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| DGXQuest Diagnostics | 20.0× |
| LHLabcorp | 25.0× |
| MTDMettler-Toledo International | 39.6× |
| ILMNIllumina | 38.4× |
| MEDPMedpace | 25.6× |
| IQVIQVIA | 19.4× |
| WATWaters | 117× |
| RVTYRevvity | 30.3× |
| AAgilent Technologies | 39.1× |
| IDXXIDEXX Laboratories | 41.5× |
| BIOBio-Rad Laboratories | 27.7× |
| Peer median | 34.3× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Quest Diagnostics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.